Hakutulokset - Wojt Janowski
- Näytetään 1 - 3 yhteensä 3 tuloksesta
-
1
Daratumumab, cyclophosphamide, bortezomib and dexamethasone for non-transplant eligible myeloma (AMaRC 03-16) Tekijä Peter Mollee, John Reynolds, Wojt Janowski, Hang Quach, Philip Campbell, Simon Gibbs, Sophie Lee, Edwin Lee, Kerry Taylor, Tara Cochrane, Craig T. Wallington‐Beddoe, Fiona Kwok, N Weber, Ian Kerridge, Helen Weston, P. Joy Ho, Michael F. Leahy, Noemi Horvath, Andrew Spencer
Julkaistu 2024Artigo -
2
Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study Tekijä Emma Searle, Hang Quach, Sandy W. Wong, Luciano J. Costa, Cyrille Hulin, Wojt Janowski, Jesús G. Berdeja, Sébastien Anguille, Jeffrey Matous, Cyrille Touzeau, Anne‐Sophie Michallet, Marla Husnik, Deeksha Vishwamitra, Zhuolu Niu, Julie S. Larsen, Ling‐Ling Chen, Jenna D. Goldberg, Rakesh Popat, Andrew Spencer
Julkaistu 2022Artigo -
3
Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion Tekijä Constantine S. Tam, Tadeusz Robak, Paolo Ghia, Brad S. Kahl, Patricia Walker, Wojt Janowski, David Simpson, Mazyar Shadman, Peter Ganly, Luca Laurenti, Stephen Opat, Monica Tani, Hanna Ciepłuch, Emma Verner, Martin Šimkovič, Anders Österborg, Marek Trněný, Alessandra Tedeschi, Jason C. Paik, Sowmya B. Kuwahara, Shibao Feng, Vanitha Ramakrishnan, Aileen Cohen, Jane Huang, Peter Hillmen, Jennifer R. Brown
Julkaistu 2020Artigo
Työkalut:
Liittyvät aiheet
Gastroenterology
Internal medicine
Medicine
Chemotherapy
Daratumumab
Multiple myeloma
Oncology
Surgery
Adverse effect
Astronomy
Bortezomib
Chemoimmunotherapy
Chronic lymphocytic leukemia
Cyclophosphamide
Dexamethasone
Environmental health
Immunology
Ionosphere
Lenalidomide
Leukemia
Neutropenia
Overall survival
Physics
Population
Progression-free survival
Randomization
Randomized controlled trial
Regimen
TEC